ABSTRACT
Objective@#To investigation HER2 status in gastric adenocarcinoma of Chinese and contributing factors to the HER2 expression. @*Methods@#HER2 status of 40 842 gastric adenocarcinomas and clinical data were retrospectively collected from 23 hospitals dated from 2013 to 2016. The association between HER2 positivity and clinicopathologic features was analyzed. @*Results@#Of the 40 842 patients the median age was 62 years, the male female ratio was 2.6∶1.0. The rate of HER2 positivity was 8.8% (3 577/40 842). HER2 expression was related to the tissue type, tumor location, Lauren classification and tumor differentiation (P values: 0.009, 0.001, <0.01 and <0.01, respectively). Different HER2 expression status was observed between primary and recurrent tumors in 7.6% (48/635) cases. The rates of HER2 positivity ranged from 2% to 10% among different institutions. The rates of HER2 FISH amplification were dramatically different among the 23 hospitals (0-100%) with an average rate of 10% (810/8 156) in patients with HER2 IHC 2+ . @*Conclusions@#HER2 expression is associated with clinicopathologic characteristics. HER2 re-assessment of tumor tissue and use of in situ hybridization techniques increase HER2 positivity. The current retrospective study should reflect the HER2 status in gastric adenocarcinoma of Chinese patients.
ABSTRACT
[This corrects the article DOI: 10.1186/s12935-016-0317-2.].
ABSTRACT
BACKGROUND: Since cytotoxic T cell (CTL) response is the major cellular type in attacking tumor cells, most immunotherapy targets to manipulate the CTL response. Immunotherapies targeting melanoma-specific antigens (MAGEs), a group of tumor-specific shared antigen, have shown to be promising. Our previous study has shown that MAGE1/TBHSP70 and MAGE3/TBHSP70 could induce a robust immune response against B-16 melanoma cells in C57BL/6 mice. In this study, we used an animal model to further demonstrate MAGEs as a potential immunotherapy target for tumorigenesis in vivo. METHODS: In the current study, we developed a MAGE1/MAGE3/TBHSP70 recombinant protein vaccine and evaluated its protective efficacy against tumor development by challenge vaccine-immunized mice with MAGE-expressing human tumor cell lines in a Hu-PBL-SCID mouse model. The cellular immune reactions were monitored by ELISPOT and cytotoxicity assays. RESULTS: Splenocytes isolated from vaccine-immunized mice presented potent cytokine secretion capacity and CTL-specific cytotoxic. Vaccine-immunized mice had a significant tumor regression and prolonged survival compared with controls (both p < 0.05). In vitro, rMAGE1-MAGE3-TBHSP70 showed a potent tumor-antigen-specific immune response in both hepatocellular carcinoma and pulmonary carcinoma cell lines. CONCLUSION: This newly-developed recombinant protein vaccine may serve as a new immunotherapy for cancer.
ABSTRACT
Gastroenteropancreatic neuroendocrine neoplasms are a rare, heterogeneous group of neoplasms. The incidence has increased greatly during the past 40 years, partially due to the advanced endoscopic and imaging techniques. As a type of neoplasm with the specific morphology and immunophenotype, its nomenclature and classification have also been changed considerably over the past 40 years, from the past "carcinoid" to the current "neuroendocrine neoplasm". WHO currently recommends two-tiered classification, neuroendocrine tumors and neuroendocrine cancer, according to the differentiation, morphology and proliferation index. However, the neoplasms from different sites have different phenotypes, biological behaviors, and accordingly the different staging systems for the indication on prognosis and therapy selection. Recent research indicates that the tumor from different sites could express different molecular markers which are useful for the further study of molecular features, as well as the evaluation of the site of primary tumor. Along with the progress of the research on molecular mechanisms, including signal transduction, epigenetics and tumor microenviroment, the mode of diagnosis and treatment would also be changed accordingly. In this article, new advances in classification, clinical and pathological features and molecular mechanism of gastroenteropancreatic neuroendocrine neoplasms will be reviewed.
Subject(s)
Humans , Epigenesis, Genetic , Incidence , Neoplasm Staging , Neuroendocrine Tumors , Classification , Diagnosis , Therapeutics , Phenotype , Prognosis , Signal Transduction , Tumor MicroenvironmentABSTRACT
Chinese medical student's education system is quite different from that in western countries.Besides,Chinese residency training program is just starting.The professional training of pathologists,who make the final diagnosis in the hospital,is not satisfied.The present situation in China is that overall quality of pathologists is low and varied.The pathology department of Xijing Hospital started to carry out the pathology residency training program since 2009.It is expected to search for a model of pathology residency training program with Chinese characteristics.
ABSTRACT
AIM: To prepare Nano-Liposome encapsulated MAGE3/HSP70(NL M3H) and study its character and antitumor immunity in mouse. METHODS: NL M3H was prepared by the thin film-dispersion ultrasonic. The shape and size of NL M3H were detected by electron microscope. The encapsulation rate, drug-carrying capacity, stability and the releasing character were tested by Sephedex-G100 gel filtration. The mouse was immunized by NL M3H, and the antitumor immunity was detected by ELISPOT and LDH release assay. RESULTS: The mean size of NL M3H was lower than 100 nm. The encapsulation rate was 38％.The drug content was 0.038 g/L. NL M3H has good stability after stored in 4℃ for 6 months. The releasing profile showed that 74 percent of proteins was released during the first 24 hours in saline. The results of ELISPOT and LDH release assay showed that NL M3H generated tumor specific cytotoxic T lymphocyte(CTL)to damage tumor cel1. CONCLUSION: NL M3H has novel characters, it can generate specific CTL to kill tumor cell, and can be used as new kind of vaccine agsinst tumor.
ABSTRACT
Aim To obtain the HCC cell lines which could coexpressed the B7.1 and SEA. Methods The positive clones expressing the B7.1 and SEA were screened by immunohistochemical staining. The amount of SEA in culture supernatant was detected by ELISA. Results HCC cell clones coexpressing B7.1 and SEA were obtained, and expression amount of SEA in culture supernatant reached 10～ 14× 10-8g/L. Conclusion The co-rec-ogenition immune effective system of SEA and B7.1 on HCC cells is established.
ABSTRACT
Objective:To construct the prokaryotic expression vector of SEA mutant gene SEA(D227A).The gene was expressed in E.Coli, and the induced protein was purified and identified.Methods:The SEA gene was cloned by PCR from Staphylococcus aureus strain FRI 100.D227A was introduced by changing the Asp codon GAT into GCT(Ala)in the primer.The expression plasmid pRSET SEA(D227A)was constructed and transformed into E.Coli BL21(DE3)pLysS.The induced protein was identified by Western blot.Results:The nucleotide sequence of SEA(D227A)was found to be identical to the designed sequence. E.Coli BL21(DE3)pLysS contained pRSET SEA(D227A)can express a 32 kD protein which can specially bind with the anti SEA mAb.The induced protein was purified with Ni 2+ system.Conclusion:The SEA(D227A)gene was constructed and expressed successfully.The study gave a clue to the research of low toxic superantigen. [
ABSTRACT
Objective:Study the relationship of HLA I and B7 1 to elucidate the role of costimulatory molecule on antigen presentation in immunological rejection.Methods:FCM was applied to detect the expression of B7 1 Then the cytotoxicity of PBML was observed before and after blocking the HLA I Results:The level of HLA I expression increased greatly(P
ABSTRACT
Objective:To construct the eukaryotic expressed vector which express recombinant toxin CD80 Linker SEA and predict the rationality and feasibility of the linker Methods:Utilize the sequence analysis software to analyze the flexibility、antigenicity、Hoop&Woods hydrophilicity and episode of recombinant toxin CD80 Linker SEA Results:Through the analysis of the software,it could be found that the recombinant toxin has correct domains of CD80 and SEA The linker has low episode、low antigenicity and high flexibility Conclusion:The results of computer analysis could help us to rationally design the recombinant toxin CD80 Linker SEA and keep it's maximum biological activity
